Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha- reductase

被引:5
作者
Polat Ö. [1 ]
Özbey I. [1 ]
Gül O. [1 ]
Demirel A. [1 ]
Bayraktar Y. [1 ]
机构
[1] Department of Urology, Atatürk Univ. Sch. of Medicine, Research Hospital, Erzurum
关键词
Benign Prostatic Hyperplasia; Finasteride; Prostatic Volume; Residual Volume; International Urology;
D O I
10.1007/BF02550930
中图分类号
学科分类号
摘要
We studied the effects of 5 alpha-reductase inhibitor (finasteride) in the treatment of benign prostatic hyperplasia (BPH). This study is a randomized controlled trial. Sixty-two patients were treated with 5 alpha- reductase (finasteride 5 mg/day) and 61 patients (control group) with placebo for one year. Prostatic volume, maximal urine flow rate, AUA symptom scoring, residual urine volume and prostate-specific antigen (PSA) levels were evaluated at 3, 6, 9 and 12 months. In the lust 6 months prostatic volume decreased rapidly (20.5%), in the second 6 months it decreased slowly and reached the maximal rate (23.3%). Maximal urine flow rate increased in the second 6 months. AUA symptom scores decreased first at 3 months and were 4.6 points lower at the end of the 12th month. There were no significant changes in residual volume. The 5 alpha-reductase inhibitor caused a 50% decrease in PSA levels, like in other studies. Because of the prolonged use of the drug, treatment with 5 alpha-reductase inhibitor is not tolerated by many patients and being expansive its future in the pharmacotherapy of BPH is unclear.
引用
收藏
页码:323 / 330
页数:7
相关论文
共 50 条
[31]   5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer [J].
Robinson, David ;
Garmo, Hans ;
Holmberg, Lars ;
Stattin, Par .
CANCER CAUSES & CONTROL, 2015, 26 (09) :1289-1297
[32]   Long-term treatment of Benign Prostatic Hyperplasia with the combination of alpha blockers and 5-alpha reductase inhibitors [J].
Ozer, Cevahir ;
Tekin, Mehmet Ilteris .
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (04) :263-266
[33]   Evaluation of Sex Hormone Levels in Benign Prostatic Hyperplasia Patients Treated with 5 Alpha-Reductase Inhibitor (Finasteride) in Amara city/Iraq [J].
Hashim, Nidhal A. ;
Khalifa, Ahmed A. ;
Mohammed, Mukhtar K. .
BAGHDAD SCIENCE JOURNAL, 2020, 17 (01) :1-8
[34]   Symptomatic benign prostatic hyperplasia: the role of 5-alpha-reductase inhibitors in the prevention of acute urinary retention and surgical therapy [J].
Marigliano, Norma ;
Galasso, Domenico .
ITALIAN JOURNAL OF MEDICINE, 2012, 6 (01) :57-62
[35]   Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor [J].
O'Leary, MP ;
Roehrborn, C ;
Andriole, G ;
Nickel, C ;
Boyle, P ;
Höfner, K .
BJU INTERNATIONAL, 2003, 92 (03) :262-266
[36]   Therapeutic role of Glycyrrhiza Uralensis fisher on benign prostatic hyperplasia through 5 alpha reductase regulation and apoptosis [J].
Park, Ja Yeon ;
Park, Woo Yong ;
Park, Jinbong ;
Ahn, Kwang Seok ;
Lee, Jun Hee ;
Kwak, Hyun Jeong ;
Um, Jae-Young .
PHYTOMEDICINE, 2022, 105
[37]   5-ALPHA-REDUCTASE INHIBITION BY FINASTERIDE (PROSCAR(R)) IN EPITHELIUM AND STROMA OF HUMAN BENIGN PROSTATIC HYPERPLASIA [J].
WEISSER, H ;
TUNN, S ;
DEBUS, M ;
KRIEG, M .
STEROIDS, 1994, 59 (11) :616-620
[38]   5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia [J].
Wallner, Lauren P. ;
DiBello, Julia R. ;
Li, Bonnie H. ;
Van Den Eeden, Stephen K. ;
Weinmann, Sheila ;
Ritzwoller, Debra P. ;
Abell, Jill E. ;
D'Agostino, Ralph, Jr. ;
Loo, Ronald K. ;
Aaronson, David S. ;
Richert-Boe, Kathryn ;
Horwitz, Ralph I. ;
Jacobsen, Steven J. .
MAYO CLINIC PROCEEDINGS, 2016, 91 (12) :1717-1726
[39]   Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 2 [J].
Zhao, Yani ;
Zhang, Yan ;
Li, Yao ;
Yang, Min ;
Yuan, Jiani ;
Cao, Yu ;
Xu, Lu ;
Ma, Xuexinyu ;
Lin, Sisong ;
An, Junming ;
Wang, Siwang .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 908
[40]   Consensus Report on Controversial Use of 5-Alpha-Reductase Inhibitor in Patients with Benign Prostatic Hyperplasia under Taiwan National Health Insurance Regulations [J].
Chuang, Te-Yen ;
Wang, Chung-Cheng ;
Chen, Po-Cheng ;
Kao, Ming-Hong .
UROLOGICAL SCIENCE, 2019, 30 (03) :131-135